A synopsis of individual key papers that evidence improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.
Annual Number of Candidates for TAVI Per Country: Current Estimates and Future Projections
Authors: Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, et al.
Citation: Eur Heart J. 2018 Jul 21;39(28):2635-2642.
doi: 10.1093/eurheartj/ehy107.
Period of study: January 2017
The Vancouver 3M Clinical Pathway Facilitates Safe Next-Day Discharge Home
Authors: Wood DA, Lauck SB, Cairns JA, Humphriees KH, et al.
Citation: JACC Cardiovasc Interv. 2019;12:459–68
DOI:10.1016/j.jcin.2018.12.0020.
Period of study: March 2015 and April 2017
Optimising patient discharge management after transfemoral TAVI: The European FAST-TAVI trial
Authors: Barbanti M, van Mourik MS, Spence MS, Iacovelli F, et al.
Citation: EuroIntervention. 2019;15:147–54
DOI:10.4244/EIJ-D-18-01197.
Patient enrolment: May 2015 – October 2017
Vancouver TAVR Clinical Pathway. Min. Approach, Standardized Care, and Discharge Criteria to Reduce LoS
Authors: Lauck SB, Wood DA, Baumbusch J, Kwon J-Y, et al.
Citation: Circ Cardiovasc Qual Outcomes. 2016;9:312–21. DOI:10.1161/CIRCOUTCOMES.115.002541.
Period of study: May 2012 to October 2014
Comparison of local versus general anesthesia in patients undergoing TAVR: A meta-analysis
Authors: Villablanca P.A, Mohananey D, Nikolic K, Bangalore S, et al.
Citation: Catheter Cardiovasc Interv. 2018;91:330–42
DOI: 10.1002/ccd.27207.
Period of study: Meta-analysis of studies 2008–2016
Length of stay after transfemoral TAVR: an analysis of the STS/ACC TVT Registry
Authors: Wayangankar SA, Elgendy IY, Xiang Q, Jneid H, et al.
Citation: JACC Cardiovasc Interv. 2019;12:422-430.
doi:0.1016/j.jcin.2018.11.015.
Period of study: November 2011 to September 2015
TAVR versus surgical valve replacement in intermediate-risk patients: A propensity score analysis
Authors: Thourani VH, Kodali S, Makkar RR, Hermann HC, et al.
Citation: Lancet. 2016;387:2218–25
DOI:10.1016/S0140-6736(16)30073-3.
Period of study: December 2011 – November 2013
Thirty-day readmission after TAVR in the United States: Insights from the Nationwide Readmission Database
Authors: Kolte D, Khere S, Sardar MR, Gheewala N, et al.
Citation: Circ Cardiovasc Interv. 2017;10:e004472
DOI:10.1161/CIRCINTERVENTIONS.116.00472.
Period of study: January to November 2013
Transcatheter Aortic-Valve Replacement with a Balloon Expandable Valve in Low-Risk Patients
Authors: Mack MJ, Leon MD, Thourani VH, Makkar R, et al. for the PARTNER 3 Investigators
Citation: N Engl J Med. 2019;380:1695–1705
DOI: 10.1056/NEJMoal1814052.
Period of study: March 2016 – October 2017
Health Status after Transcatheter vs Surgical Aortic Valve Replacement in Low-risk Patients with Aortic Stenosis
Authors: Baron SJ, Magnuson EA, Lu M, Wang K, et al.
Citation: J Am Coll Cardiol. 2019;74:2833–42
DOI:10.1016/j.jacc.2019.09.007.
Period of study: March 2016 and October 2019
Effective Operational Management in the Cardiac Catheterization Laboratory (Review paper)
Authors: Reed GW, Tushman ML, Kapadia SR.
Citation: J Am Coll Cardiol. 2018;72:2507–17
DOI:10.1016/j.jacc.2018.08.2179.
Period of study: –
SCAI/ACVP expert consensus statement on cardiovascular catheterization laboratory economics
Authors: Blankenship JC, Choi JW, Das TS, McElgunn PM, et al.
Citation: Catheter Cardiovasc Interv. 2019; 94: 123–35
DOI:10.1002/ccd.28330.
Patient enrolment: May 2015 – October 2017
The cost-effectiveness of TAVR in low surgical risk patients with severe aortic stenosis
Authors: Tam DY, Azizi PM, Fremes SE, Chikwe J, et al.
Citation: Eur Heart J Qual Care Clin Outcomes. 2020 Jul 9;qcaa058. DOI: 10.1093/ehjqcco/qcaa058.
Period of study: –
Summarising the evidence for improved patient outcomes and increased economic benefit with a TAVI procedure vs alternative pathways, taking into account organisational efficiency, budget considerations, patient choice and how to implement change in your organisation.
Management of severe symptomatic aortic stenosis in the age of COVID-19: A key paper summary
Read the key paper summary showing TAVI as the treatment of choice for all-risk ssAS patients carries even greater benefits during and post-COVID-19.
Improving care pathways: Permanent Pacemaker Insertion after TAVI
TAVI pathways need to be mapped out with PPI built into the patient journey with a consistent approach that optimises patient outcomes and service efficiency.
This content is sponsored by Edwards Lifesciences
Ⓒ Cogora 2021
Cogora Limited, 140 London Wall, London EC2Y 5DN, Registered in the United Kingdom. Reg. No. 2147432
